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Abstract 
Objective: Extended nitric oxide (NO) analysis offers the partitioned monitoring of 
inflammation in central and peripheral airways. Different mathematical models are used to 
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estimate pulmonary NO dynamics in asthma with variable results and limitations. We aimed 
to establish a protocol for extended NO analysis in patients with differing asthma severity.    
Methods: Forty patients with stable asthma and twenty-five matched control subjects were 
recruited. Exhaled NO was measured at constant flow rates between 10 and 300 mL/s. 
Twelve controls performed NO measurements weekly for four weeks.  
Results: The proportions of patients with technically acceptable measurements at 10-30-50-
100-150-200-250-300 mL/s exhalation flow rates were 8-58-100-98-98-95-90-80%, 
respectively. Alveolar NO (CANO) and total flux of NO in the conducting airways (JawNO) 
were calculated with the linear method from NO values measured at 100-150-200-250 mL/s 
exhalation flows. The mean intra-subject bias for JawNO and CANO in controls was 0.16 nL/s 
and 0.85 ppb, respectively. Both JawNO (1.31 /0.83-2.97/ vs. 0.70 /0.54-0.87/ nL/s, p<0.001) 
and CANO (4.08 /2.63-7.16/ vs. 2.42 /1.83-2.89/ ppb, p<0.001) were increased in patients 
with asthma compared to controls. In patients, CANO correlated with RV/TLC (r=0.58, 
p<0.001), FEF25-75% (p=0.02, r=-0.36) and DL,CO (r=-0.46, p=0.004). JawNO was not related 
to lung function parameters.  
Conclusions: Calculation of alveolar NO concentration with the linear method from values 
obtained at medium flow rates (100-250 mL/s) is feasible even in asthmatic patients with 
severe airflow limitation and may provide information on small airways dysfunction in 
asthma.  
Word count of the abstract: 237  
Word count of the body of the manuscript: 3079 
Number of tables: 2 
Number of figures: 5  
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Introduction 
Bronchial asthma is a heterogeneous disease characterized by accumulation of inflammatory 
cells in the airways, hypertrophy and hyperplasia of airway smooth muscle layer, increased 
mucus production, and airway wall remodelling (1). Inflammatory changes take place 
simultaneously in central and distal airways and in the alveoli (2-4). The assessment of 
airway inflammation at these different localizations can aid better understanding of disease 
pathomechanism and facilitate the development of more targeted therapies.  
Airway inflammation can be studied non-invasively by measuring the exhaled nitric oxide 
(NO) concentration. The two-compartment model allows the evaluation of NO dynamics in 
the large central or bronchial and in more distal airways (small airways and the 
alveolar/acinar region) (5, 6). For this purpose, measurements are performed at multiple 
expiratory flow rates (10-500 mL/s) and mathematical models are applied (6). The recent 
technical standard task force report of the European Respiratory Society recommends the use 
of NO plateau values measured at least at three different exhalation flows and proposes 
several mathematical equations to calculate bronchial and alveolar NO parameters (7). 
However, there are currently no standardized method that can reliably be applied to asthmatic 
patients with varying airflow limitation, smoking status and disease severity. 
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Therefore, in this study we aimed to establish a feasible method for the partitioned 
measurement of exhaled NO in asthma. Patients and control subjects carried out expiratory 
manoeuvres at a broad range of flows. We established a protocol for the calculation of central 
bronchial and peripheral airway NO parameters with low week-to-week variation. 
Furthermore, we compared central and peripheral airway inflammation between patients and 
control subjects and correlated NO variables to clinical parameters in asthma.  
Materials and Methods 
Subjects 
Patients were recruited at the Outpatient Clinic of Department of Pulmonology at 
Semmelweis University, Budapest, Hungary. They complained of symptoms consistent with 
the asthma diagnosis, they showed positivity for at least one airway allergen at skin prick 
testing or serum specific IgE testing. Patients presented documented airflow limitation, and 
they had airway hyperresponsiveness or were positive for bronchodilator reversibility during 
prior testing (1). A change in asthma therapy was not required in 4 weeks prior to the 
recruitment. Main exclusion criteria were other chronic respiratory diseases, asthma 
exacerbation in the previous 4 weeks, and signs of acute respiratory infections in the 2 weeks 
before recruitment. Healthy control subjects were recruited among employees working at the 
Department. Main exclusion criteria for controls were allergic airway disease or chronic 
respiratory disease in history, systemic steroid or antibiotic treatment in the previous 4 weeks, 
and signs of acute respiratory infections in the previous 2 weeks. Patient and control subjects 
were considered ex-smokers if they had stopped smoking at least 6 months before inclusion. 
The study was approved by the ethics committee, and all procedures were in accordance with 
the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 
Informed consent was obtained from all individual participants included in the study. 
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Measurements were performed between 10 a.m. and 3 p.m. from 1 December 2015 until 30 
November 2017.  
 
Study design 
Clinical study: Twenty-five control subjects and 40 patients with asthma were recruited. 
Medical history was noted, blood leukocyte count and CRP concentration were measured, 
exhaled nitric oxide concentration was recorded, and lung function tests were performed. 
Exhaled nitric oxide measurements were performed before lung function tests in all cases. 
Furthermore, patients filled out the Asthma Control Test (ACT) (8).  
Repeatability study: Exhaled NO measurements were repeated at a weekly basis for 4 weeks 
in twelve control subjects, who also participated in the clinical study.   
 
Nitric oxide measurements at multiple constant exhalation flow rates 
Subjects were asked not to use inhaled medication, refrain from eating, drinking and smoking 
2 hours prior to measurement. Exhaled NO concentration was measured during a manoeuvre 
starting from total lung capacity at the expiratory flows of 10-30-50-100-150-200-250-300 
mL/s with a chemiluminescent analyser (Sievers Nitric Oxide Analyzer i280, GE Analytical 
Instruments, Boulder, Co, USA). Instrument calibration was performed daily according to the 
manufacturer’s instructions. The background NO concentration was < 5 ppb. Restrictors, as 
provided and calibrated by the manufacturer, were applied to generate the required expiratory 
flows and ensure the closure of the velum during expiration. Manoeuvres at different flows 
with a duration of ≥ 20 s (10 mL/s exhalations flow), ≥ 10 s (30 mL/s), ≥ 6 s (50 and 100 
mL/s) and ≥ 5 s (150, 200, 250 and 300 mL/s) were considered sufficient. Subjects received 
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visual feedback of the expiratory flow during the entire manoeuvre. Plateau values of NO 
recordings were identified manually. Recordings corresponding to the initial expiratory 
volume of 150 mL air (i.e. anatomic dead space) were disregarded. We considered a 
recording technically acceptable and valid if the plateau NO concentration was in a 3-second 
window with minimal sloping (9) where the actual exhalation flow was ± 10% of the target 
rate in compliance with the recommendations for FENO50 (fractional exhaled nitric oxide 
concentration at 50 mL/s exhalation flow) analysis. The mean values of two NO recordings 
with < 10 % difference were used for further calculations.  
 
Calculation of CANO and JawNO 
Data were analysed based on the two-compartment model using the linear method of 
Tsoukias et al. (5-7), which estimates acinar/alveolar NO (CANO) as the measure of the distal 
airways and total flux of NO in the conducting airway compartment (JawNO) as a marker of 
central airways. 
 
Other variables 
Leukocyte count (Sysmex XE-2100, Sysmex Corporation, Kobe, Japan) and serum CRP 
concentration (Beckman Coulter AU680, Beckman Coulter Inc., Indianapolis, IN, USA) were 
determined from venous blood samples (asthma: N=38, control N=25). Measurements for 
spirometry, body plethysmography and diffusion capacity were performed according to 
current guidelines (PDT-111, Piston, Budapest, Hungary) (10-12). Two patients with asthma 
could not perform the manoeuvre for diffusion capacity measurement. An ACT score ≤ 19 
referred to uncontrolled asthma (8).  
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Statistical analysis 
Demographic data were compared with unpaired t-test and expressed as mean ± standard 
deviation, categorical variables were compared with the Fisher’s exact test. Inhaled 
corticosteroid (ICS) doses, blood eosinophil percentage, CRP value, FENO50, JawNO and 
CANO data did not show a normal distribution (D’Agostino-Pearson normality test), therefore 
these variables were analysed with non-parametric tests (Mann-Whitney, Kruskal-Wallis with 
Dunn’s post-hoc and Spearman tests) and expressed as median /interquartile range/. 
Measurement repeatability was assessed using the Bland-Altman plot (13). P<0.05 was 
considered significant (GraphPad Prism 5.0, GraphPad Software, San Diego, USA). Multiple 
regression analysis with smoking habits as covariates were used to assess relationship 
between CANO and lung function measures (Statistica 13.2, StatSoft, Tulsa, USA).   
The sample size of the clinical study was calculated to reach a statistical power (1-β) of 0.80 
and effect size of 0.75 with respect to the asymptotic relative efficiency of non-parametric 
tests. This effect size was based on the variability of JawNO and CANO data in the 
repeatability study.       
 
Results 
Subject characteristics 
The main clinical characteristics of patients and control subjects are shown in Table 1. 
Patients were treated at treatment steps of GINA 1 (steroid-naïve, n=7), GINA 3-4 (moderate-
severe, n=16) and GINA 5 (severe on anti-IgE therapy, n=17) (1). Forty percent of patients 
had uncontrolled asthma according to the ACT scores.  
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Measurements of exhaled NO at different constant exhalation flow rates  
Subjects performed exhalation manoeuvres at various constant flows (10-300 mL/s) both in 
the repeatability and clinical studies (number of measurements/flow in controls subjects: 61, 
in patients with asthma: 40; Table 2). Only a fraction of patients could perform a manoeuvre 
with a technically acceptable recording at very low flow rates (<50 mL/s), while the majority 
of manoeuvres were technically correct at higher flows (>50 mL/s). Therefore, for the 
extended NO analysis only the linear model could be applied (7), and NO values obtained at 
100, 150, 200 and 250 mL/s expiratory flow rates were used as inputs for the calculation of 
JawNO and CANO (asthma: r=0.98 ± 0.03, control: r=0.98 ± 0.02). As four patients could not 
perform the manoeuvre at 250 mL/s exhalation flow, values at 300 mL/s were included in the 
model in three cases. Using this strategy, 92.5% of all calculations in asthma were executed 
on data at 4 flow points (2.5% at 3 flow rates, 5% at 2 flow rates). Data obtained at 4 flow 
rates were used to calculate JawNO and CANO in each control volunteer. All subjects could 
perform valid manoeuvres for FENO50. Exhaled NO concentrations were elevated in asthma 
at all flow rates between 50 and 250 mL/s (p<0.001, Figure 1).  
 
Intra-subject repeatability of JawNO and CANO  
Weekly JawNO values in control subjects were 0.73 /0.59-0.73/, 0.51 /0.41-0.67/, 0.58 /0.50-
0.73/ and 0.50 /0.39-0.68/ nL/s. The Bland-Altman analysis for the lowest and highest 
individual values showed a mean difference of 0.16 nL/s (95% limits of agreement: -0.56-
0.89 nL/s; Figure 2a). CANO values at the weekly measurements were 2.64 /2.25-3.08/, 3.19 
/2.30-4.22/, 1.75 /1.17-3.12/ and 2.27 /1.89-2.86/ ppb. The Bland-Altman graph for the 
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lowest and highest individual values demonstrated a mean bias of 0.85 ppb (95% limits of 
agreement: -3.67-5.36 ppb; Figure 2b).  
 
Increased JawNO and CANO in patients with asthma 
JawNO was increased in patients with asthma compared to control subjects (1.31 /0.83-
2.97/ nL/s vs. 0.70 /0.54-0.87/ nL/s, p<0.001; Figure 3a). In asthma, JawNO showed a strong 
positive correlation with FENO50 (p<0.001, r=0.94; Figure 3b) and blood eosinophil 
percentage (p=0.001, r=0.50), but not with lung function parameters, leukocyte count, CRP 
or age (p>0.05).  
Alveolar NO concentration was higher in patients than in controls (4.08 /2.63-7.16/ ppb vs. 
2.42 /1.83-2.89/ ppb, p<0.001; Figure 4a). In asthma, CANO concentration positively 
correlated with blood eosinophil percentage (p=0.002, r=0.50), CRP concentration (p=0.001, 
r=0.50), age (p=0.003, r=0.46), RV/TLC (p<0.001, r=0.58; Figure 4c), and airway resistance 
(p=0.02, r=0.38). It inversely correlated with FEV1 % predicted (p=0.03, r=-0.34), FEF25-75% 
% reference (p=0.02, r=-0.36; Figure 4b), and diffusion capacity of the lung for carbon 
monoxide (p=0.004, r=-0.46; Figure 4d). We found a significant positive correlation between 
CANO and JawNO (p=0.005, r=0.44), and between CANO and FENO50 (p<0.001, r=0.60).  
The association of CANO to RV/TLC and DL,CO remained significant in patients with asthma 
when using multiple regression analysis with smoking status (beta=0.48, p=0.003 and beta=     
-0.45, p=0.005) or packyears (beta=0.46, p=0.007 and beta=-0.43, p=0.007) as a covariate. 
However, the relationship between CANO and FEF25-75% % reference became statistically 
insignificant in a model controlled for smoking status (p=0.09) or packyears (p=0.14). 
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The effect of smoking status on NO parameters 
We also analysed non-smoking and ex-/current smoking control subjects and patients in 
separate subgroups. There was an increase in JawNO in patients compared to controls with 
relevant smoking status (control vs. asthma in non-smokers: 0.68 /0.61-0.78/ nL/s vs. 1.22 
/0.79-2.52/ nL/s, p=0.001 and in smokers: 0.75 /0.26-1.00/ nL/s vs. 1.64 /0.95-0.3.67/ nL/s, 
p=0.009; Figure 5a). Likewise, CANO was higher in asthma than in control subgroups 
(control vs. asthma in non-smokers: 2.48 /1.83-3.04/ ppb vs. 3.75 /2.46-6.35/ ppb, p=0.04 and 
in smokers: 2.04 /1.82-2.66/ nL/s vs. 5.70 /3.86-13.81/ ppb, p=0.001; Figure 5b). We found 
no difference in JawNO and CANO between non-smokers and smokers within the control 
(p=0.99 and p=0.99) and asthmatic (p=0.99 and p=0.23) groups. 
 Discussion 
The inflammation and dysfunction of small airways are related to important clinical aspects 
of asthma such as airway hyper-responsiveness (14) or exacerbation risk (15), therefore 
targeted anti-inflammatory treatment which can mitigate small airways inflammation can 
convey clinical benefit. However, the non-invasive assessment of distal lung inflammation is 
an unmet need in clinical practice. Models using exhaled NO concentration measured at 
different flow rates allow the partitioned assessment of airway inflammation in central and 
distal airways. The European Respiratory Society technical standard document provides 
details for mathematical modelling of pulmonary NO dynamics and highlights the need for 
further studies (16). In this study, we presented a feasible protocol for alveolar NO 
measurement and showed that inflammation and dysfunction of small airways are related in 
asthma. 
In our study, patients performed exhalation manoeuvres at constant flow rates between 10 
and 300 mL/s, but we could measure exhaled NO concentrations at low flow rates only in a 
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minority of patients with asthma. Similarly, Gelb et al. also noted that measurements were 
not reproducible at low exhalation flows (≤ 50 mL/s) in asthmatics with FEV1 < 80% 
predicted (17), representing a significant number of treated patients in clinical settings. In 
addition, we also observed some failure in manoeuvre performance at 300 mL/s exhalation 
flow, which questions the feasibility of applying very high flow rates in this population. Up 
to 30% of patients with severe asthma had to be excluded from previous studies due to 
negative CANO values, suggesting inadequate models and the requirement of additional flow 
rates (18, 19). However, we established a linear model based on exhaled NO values at four 
flow points (100, 150, 200 and 250 mL/s), which could be successfully and reliably applied 
to measure alveolar NO concentrations in patients with differing asthma severity and 
smoking history.  
We confirm previous findings that alveolar NO concentration is increased in a mixed group 
of asthmatic patients with mild-to-severe disease compared to matched control subjects (17). 
Other studies also showed that peripheral airway inflammation, as reflected by CANO, is 
elevated in clinically important phenotypes of asthma: in patients with refractory asthma on 
high ICS dose compared to mild-to-moderate asthma (20), in patients with steroid-dependent 
severe asthma compared to severe asthmatics on high dose ICS (19) and in subjects with  
nocturnal symptoms (21). Several authors observed that alveolar NO concentration could not 
be modified by initiating ICS therapy or increasing its dose (22, 23). While a decrease in 
CANO was reported after oral steroid therapy in some studies (17, 20), interestingly, others 
found no treatment effect (23). This suggests that despite ongoing anti-inflammatory 
treatment, increased inflammation in peripheral airways is a distinct disease characteristic in 
certain asthma phenotypes, which is also steroid-resistant in some cases. Hence, the extended 
NO analysis might facilitate the identification and better understanding of asthma subgroups, 
and it can also aid monitoring of novel anti-inflammatory therapies.    
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We analysed the relationship between alveolar NO concentration and physiological measures 
of distal lung dysfunction. We reported a moderate correlation between CANO and RV/TLC, 
which is a known marker of air trapping and hyperinflation in severe and non-severe asthma 
(24). This finding extends the results of a previous study that showed a similar, but stronger 
correlation between the two parameters in severe asthma (18). In our study, there was a weak 
correlation between CANO and FEF25-75%, which was not present when the analysis was 
controlled for smoking. This lung function parameter is debated to truly reflect peripheral 
airways dysfunction, partly due to its high measurement variability (25). Likewise, one study 
described a correlation with similar strength in mild-to-moderate asthma (26), but others 
found no relationship between alveolar NO concentration and FEF25-75% in mild-to-severe 
asthmatics (19). Interestingly, in our cohort CANO moderately correlated to pulmonary 
diffusion capacity, as previously observed in alveolitis (27). Besides the upregulation of the 
inducible NO synthase in alveolar epithelial cells, the decreased diffusion of NO might be 
another mechanism leading to increased CANO in asthma, nonetheless, it must be noted that 
pulmonary diffusion capacity was within the normal range in patients. Despite of the 
exploratory nature of these results, they imply that increased CANO can reflect distal airways 
dysfunction in asthma.  
It was previously shown that alveolar NO concentration is strongly associated with eosinophil 
percentage in bronchoalveolar lavage fluid in mild asthmatics (20). However, the weak-to-
moderate correlation between CANO and blood eosinophil percentage in our study suggests 
that inflammation in peripheral airways is not closely related to systemic eosinophilic 
inflammation, as already shown for FENO50 (28).   
We also reported a positive correlation between age and CANO, which was also observed in 
another cohort of asthmatic patients (29). It is known that CANO increases with age in healthy 
subjects, which could be explained by the reduced pulmonary NO diffusion resulting from 
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decreased capillary blood volume at an older age (30). It can be speculated that this 
mechanism might also be present in older patients with asthma.  
We found a close correlation between FENO50 and JawNO in asthma highlighting that these 
parameters assess inflammation at similar sites within the airways, and the additional 
information gained by the calculation of JawNO might be limited as also suggested by others 
(31).  
The weekly repeatability of CANO and JawNO in control subjects was assessed in a one-month 
period, relevant to clinical settings for asthma follow-ups. The intra-subject repeatability of 
these parameters was somewhat better in a previous study using a day-to-day setup (19), 
nevertheless, the observed difference between controls and patients exceeded the mean intra-
subject bias.  
Some authors correct alveolar NO for trumpet model and axial NO back-diffusion (32, 33). 
However, these formulae disregard the effect of central airways constriction on axial back-
diffusion, which potentially result in overcorrection (34, 35). According to the recent 
technical standard document the use of correction factors for axial back diffusion is not 
recommended (7). Therefore, we did not apply any correction in our data analysis.  
This study has limitations. Cigarette smoking is known to interfere with exhaled nitric oxide 
concentration (36), and smoking had been previously shown to decrease CANO in asthma 
(37), which was not confirmed by our findings. Importantly, CANO was elevated in asthma, 
irrespective of the smoking status. Our cohort reflects a realistic asthmatic population in 
terms of smoking habits, as approximately one third of asthmatics were also reported to be 
current or former smokers in larger cohorts (38, 39). Cigarette smoking in asthma results in 
greater morbidity, uncontrolled and more severe disease, and accelerated decline in lung 
function (40). In addition, a recent publication described that one third of patients with severe 
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asthma were active or former smokers, who presented with fixed airflow limitation and 
clustered into clinical subgroups with either Th2-high or Th2-low signatures, underlining the 
potential therapeutic relevance of measuring inflammatory markers including exhaled NO in 
these populations (41). Furthermore, this is a single-centre observational study, and our 
results should be validated by future investigations. The cross-sectional nature of the NO 
measurements does not allow to draw conclusions regarding the repeatability of CANO in 
asthma, or how it reflects disease course or therapeutic interventions.  
 
Conclusions 
The present study describes a feasible protocol for extended NO analysis to calculate alveolar 
nitric oxide concentration, a marker of distal lung inflammation. Our method can successfully 
and reliably be applied to patients with asthma of differing severity including those with 
severe disease. Alveolar NO concentration shows a weak correlation to physiological 
measures of small airways dysfunction in asthma. The application of our protocol could 
facilitate understanding the role of CANO in phenotyping asthma.  
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Tables 
Table 1. Patient characteristics 
 
 Control, N=25 Asthma, N=40 p-value 
Male/Female, N (%) 7/18 (28%/72%)  11/29 (27.5%/72.5%) 1.00 
Age, years 39±14 44±17 0.17 
Smoking status 
    Non-smoker, N (%) 
    Ex-smoker, N (%) 
    Current smoker, N (%) 
 
17 (68%) 
3 (12%) 
5 (20%) 
 
28 (70%) 
10 (25%) 
2 (5%) 
0.10 
Pack-years 24±7 18±10 0.14 
Blood eosinophil, % 1.4 /0.7-2.7/ 4.2 /2.2-5.8/ <0.001 
CRP, mg/L 2.0 /1.0-4.8/ 2.6 /1.7-5.1/ 0.47 
FEV1, %ref. 103±10 79±18 <0.001 
FVC, %ref. 107±13 95±14 0.002 
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FEV1/FVC 0.82±0.06 0.70±0.13 <0.001 
FEF25-75%, %ref. 93±18 54±28 <0.001 
RV/TLC, % 0.30±0.21 0.33±0.14 0.53 
KCO, %ref. 97±19 98±17 0.89 
DL,CO, %ref. 114±20 112±16 0.65 
ICS, N (%) NA 33 (82.5%) NA 
ICS dose, budesonide equivalent µg NA 800 /340-800/ NA 
LABA, N (%) NA 31 (77.5%) NA 
LAMA, N (%) NA 3 (7.5%) NA 
LTRA, N (%) NA 14 (35%) NA 
Oral theophylline, N (%) NA 3 (7.5%) NA 
Anti-IgE treatment, N (%) NA 17 (42.5%) NA 
Data are presented as mean ± standard deviation or median /interquartile range/ and 
compared with unpaired t-test, Mann-Whitney or chi-square tests (categorical variables). 
CRP: C-reactive protein, DL,CO: diffusion capacity of the lung for carbon monoxide, ICS: 
inhaled corticosteroid, IgE: immunoglobulin E, FEF25-75%: forced expiratory flow at 25-
75% of vital capacity, FEV1: forced expiratory volume in 1 second, FVC: forced vital 
capacity, KCO: transfer coefficient of the lung for carbon monoxide, LABA: long-acting 
β2-agonist, LAMA: long-acting muscarinic antagonist, LTRA: leukotriene receptor 
antagonist, N: number, NA: not applicable, ref.: reference, RV: residual volume, TLC: total 
lung capacity. 
Table 2. Percentage of technically acceptable exhaled NO manoeuvres with valid 
recordings at different exhalation flow rates 
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Exhalation flow, mL/s 10 30 50 100 150 200 250 300 
Control subjects 20% 79% 100% 100% 100% 100% 98% 98% 
Patients with asthma  8% 58% 100% 98% 98% 95% 90% 80% 
 
 
 
Figure captions 
Figure 1. Exhaled NO concentrations at multiple flow rates  
Exhaled NO at different constant exhalation flows in controls (a) and patients with asthma 
(b). Lines show median values. Mann-Whitney test: 
#
p<0.001 compared to corresponding NO 
concentration in controls. 
 
 
 
 
 
 
 
23 
 
 
 
 
 
Figure 2. Intra-subject repeatability of JawNO and CANO 
The weekly intra-subject repeatability of total flux of NO in the conducting airway 
compartment (JawNO; a) and alveolar nitric oxide concentration (CANO; b) in control subjects 
as shown by the Bland-Altman plot with mean difference and limits of agreement (mean 
difference ± 1.96 standard deviation).  
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Figure 3. JawNO in patients with asthma 
JawNO was increased in asthma (Mann-Whitney test; a), and strongly correlated with FENO50 
(b). Spearman correlation: ***p<0.001 
 
 
 
 
 
 
Figure 4. CANO in patients with asthma 
CANO was increased in asthma (Mann-Whitney test; a), and correlated with FEF25-75% % 
reference (b), RV/TLC (c) and DL,CO (d). Spearman correlation: *p<0.05, **p<0.01, 
***p<0.001 
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Figure 5. NO parameters in smokers and non-smokers 
JawNO (a) and CANO (b) were increased in ex- and current smoking patients with asthma 
compared to corresponding control subjects (Kruskal-Walllis with Dunn’s post-hoc test). 
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